|Videos|March 16, 2016

Dr. Michael Postow on the Toxicities of Melanoma-Treating Targeted Therapy Combinations

Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering, discusses the need for further investigation into targeted agent combinations due to high rates of toxicities in patients with melanoma. Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.

Stay up to date on practice-changing data in community practice.

Dr. Michael Postow on the Toxicities of Melanoma-Treating Targeted Therapy Combinations

Related Content

Rapid Hematologic Clearances and Promising Bone Marrow Responses in AL Amyloidosis

FDA Accepts RP1 BLA Resubmission for Advanced Melanoma

Beyond Genetic Testing: Preparing for the Era of Personalized Cancer Prevention

SEQUOIA: Zanubrutinib Holds Up in CLL’s Toughest Age Group

Beyond KOMET-007: What’s Next for Ziftomenib in AML

Latest CME

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

25th Annual International Congress on the Future of Breast Cancer® East

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

25th Annual International Congress on the Future of Breast Cancer® West

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

Rhode Island Oncology Society

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Empire State Hematology & Oncology Society (New York)

South Carolina Oncology Society

Minnesota Society of Clinical Oncology

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Colorado Oncology Society

Kansas Society of Clinical Oncology

24th Annual International Congress on the Future of Breast Cancer® East

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera

FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns

Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis

FDA Accepts RP1 BLA Resubmission for Advanced Melanoma

Beyond Genetic Testing: Preparing for the Era of Personalized Cancer Prevention